肿瘤药学Issue(3)：193-196,4.DOI:10.3969/j.issn.2095-1264.2014.038
贝伐单抗辅助培美曲塞联合顺铂化疗治疗非小细胞肺癌的临床观察
Clinical Observation on the Bevacizumab Combined with Pemetrexed plus Cisplatin in the Treatment of Non-small Cell Lung Cancer
摘要
Abstract
Objective To study the application value of Bevacizumab combined with Pemetrexed plus Cisplatin in the treat-ment of non-small cell lung cancer(NSCLC). Methods A total of 240 advanced non-small cell lung cancer patients enrolled between January 2007 and December 2008 were randomly divided into observation group which was given bevacizumab+pe-metrexed+cisplatin, and control group which was given pemetrexed+cisplatin, each group with 120 cases. Then recent and long-term therapeutic effect and adverse reaction were observed and compared. Results (1) The overall remission rate (ORR) and disease control rate (DCR) of the observation group were significantly higher than those of control group, and the differences had statistical significance(P<0.05). (2) The 1-year, 3-year and 5-year survival rate of observation group were significantly higher than those of control group. The progression free survival and overall survival time of observation group were significantly longer than those of control group. All the differences had statistical significance (P<0.05). (3) The differences of adverse reac-tions incidence rate had no statistical significance between two groups (P>0.05). Conclusion Bevacizumab combined with pemetrexed+cisplatin have positive clinical value, for it contributes to improve the remission and prolong overall survival time, meanwhile it will not increase adverse reaction of NSCLC patients.关键词
非小细胞肺癌/贝伐单抗/培美曲塞/顺铂/临床价值Key words
Non small cell Lung Cancer/Bevacizumab/Pemetrexed/Cisplatin/Clinical value分类
医药卫生引用本文复制引用
邓涛,李改丽,戎健,周辉..贝伐单抗辅助培美曲塞联合顺铂化疗治疗非小细胞肺癌的临床观察[J].肿瘤药学,2014,(3):193-196,4.基金项目
长沙市科技计划项目资助（k1307023-31）。 （）
